Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease Sanofi announced that the Europ...
Nurix Therapeutics, Inc. announced that the first patient has been enrolled in the global Phase 3 DAYBreak CLL-306 study (NCT07516093) evaluating b...
Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinica...
Pharmaceutical marketing is undergoing a significant transformation as companies balance regulatory complexity, digital disruption, evolving workforce ex...
Transformational Combination Creates a Leading Regenerative Medicine Company Across Numerous Surgical Subspecialties Accelerates MIMEDX’s Strategi...
Curium™ announced it is advancing plans for a second cyclotron investment in Romania, reaffirming the company’s long-term commitment to expan...
TARGET-D 203 trial to evaluate VS-7375 both as monotherapy and in combination with cetuximab or panitumumab in previously treated metastatic colorectal...
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bac...
-Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in the global Phase 3 YOSEMITE clinical trial of zodasir...
Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipme...
Demonstrates competitiveness of hyaluronidase-based ADC SC conversion platform Confirms stability of high-concentration ADC SC formulations and improv...
CellCarta, a leading global CRO laboratory to the biopharmaceutical industry, announced the launch of its Global Digital Pathology and AI Consortium, a cur...
Aptar Pharma, a global leader in drug delivery, dosing, protection technologies and services, announced that the UK Medicines and Healthcare ...
This agreement supports a new randomized cohort within the ARC-20 study evaluating investigational casdatifan plus tivozanib versus tivozanib a...
© 2026 Biopharma Boardroom. All Rights Reserved.
